Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (72)	10/19/2001 2:39:20 PM
From: scaram(o)uche	Respond to of 269

>> 4 of 4 had skin rash << Thanks. Given recent commentary (on CNBC?), I don't think that such would surprise Waksal. Very, very nice to know. Thanks, thanks, thanks. OK, I'll go look at the stuff. Since you've already found your way in, is there anything from TELK? (don't answer that one, as I have a list of about 20!!) ;-)

To: keokalani'nui who wrote (72)	10/19/2001 9:29:46 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 269

OT <<BTW, I've been having fun in the EGFr stuff. (Though they are hiding the ball, the abgx Mab update at the meeting might be interesting. 4 of 4 had skin rash.)>> There is no therapy based on EGF (small molecules or antibodies) without ski rash as side effects. It indicate that drug is fairly distributed and it reach all part of the body. Interesting is PFE approach (CI-1033, from WL) where drug potency isn't prime objective. Hitting almost all erbB family receptors, with longer exposure. However, I do not like irreversible. BTW, thanks for AACR-abstracts pointer. Miljenko